Literature DB >> 7705437

Vascular somatostatin receptors in synovium from patients with rheumatoid arthritis.

J C Reubi1, B Waser, H M Markusse, E P Krenning, M VanHagen, J A Laissue.   

Abstract

The peripheral nervous system and its neuropeptidergic pathways may play an important role in the pathogenesis and development of rheumatoid arthritis. In the present study, the role of the neuropeptide somatostatin (SRIF), which was recently shown to be implicated in inflammatory diseases of the gastrointestinal tract, was evaluated by measuring the expression of somatostatin receptors in synovium from patients with rheumatoid arthritis. Somatostatin receptors were detected using in vitro receptor autoradiography in the synovium from five patients with active disease. No receptors were found in one case, a successfully treated patient with quiescent disease. The receptors were of high affinity and specific for biologically active somatostatin analogs. Displacement by nanomolar concentrations of somatostatin-14, somatostatin-28, and octreotide was observed, suggesting that most of the receptors identified belong to the SRIF1A subtype. The somatostatin receptors were preferentially located in blood vessels, with specific labeling of the veins but not of the arteries. The whole vessel wall was homogeneously labeled including the smooth muscle cells and probably the endothelium. These data suggest that the synovium in active rheumatoid arthritis expresses a high density of somatostatin receptors. Somatostatin may act through these venous receptors to influence the inflammatory process by induction of vasoconstriction, inhibition of plasma extravasation and cell migration, or inhibition of neovascularization.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7705437     DOI: 10.1016/0014-2999(94)90796-x

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  10 in total

Review 1.  Octreoscan radioreceptor imaging.

Authors:  Aart J van der Lely; Wouter W de Herder; Eric P Krenning; Dik J Kwekkeboom
Journal:  Endocrine       Date:  2003-04       Impact factor: 3.633

Review 2.  Somatostatin receptor scintigraphy in thoracic diseases.

Authors:  P Ameri; F Gatto; M Arvigo; G Villa; E Resmini; F Minuto; G Murialdo; D Ferone
Journal:  J Endocrinol Invest       Date:  2007-11       Impact factor: 4.256

3.  Current imaging strategies in rheumatoid arthritis.

Authors:  Merissa N Zeman; Peter Jh Scott
Journal:  Am J Nucl Med Mol Imaging       Date:  2012-03-28

4.  Protein-Losing Enteropathy and Gastropathy.

Authors:  Brian R. Landzberg; Mark B. Pochapin
Journal:  Curr Treat Options Gastroenterol       Date:  2001-02

Review 5.  Systematic Review: Targeted Molecular Imaging of Angiogenesis and Its Mediators in Rheumatoid Arthritis.

Authors:  Fatemeh Khodadust; Aiarpi Ezdoglian; Maarten M Steinz; Judy R van Beijnum; Gerben J C Zwezerijnen; Gerrit Jansen; Sander W Tas; Conny J van der Laken
Journal:  Int J Mol Sci       Date:  2022-06-25       Impact factor: 6.208

6.  Octreotide regulates CC but not CXC LPS-induced chemokine secretion in rat Kupffer cells.

Authors:  Vassilis Valatas; George Kolios; Pinelopi Manousou; George Notas; Costas Xidakis; Ioannis Diamantis; Elias Kouroumalis
Journal:  Br J Pharmacol       Date:  2004-01-12       Impact factor: 8.739

7.  Somatostatin inhibits tooth-pulp-evoked rat cervical dorsal horn neuronal activity.

Authors:  M Takahashi; M Takeda; S Matsumoto
Journal:  Exp Brain Res       Date:  2008-01-09       Impact factor: 1.972

8.  Somatostatin receptor imaging by SPECT and PET in patients with chronic inflammatory disorders: a systematic review.

Authors:  Luz Kelly Anzola; Andor W J M Glaudemans; Rudi A J O Dierckx; F Andres Martinez; Sergio Moreno; Alberto Signore
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-08-28       Impact factor: 9.236

Review 9.  Sjögren Syndrome: New Insights in the Pathogenesis and Role of Nuclear Medicine.

Authors:  Anzola Luz Kelly; Rivera Jose Nelson; Ramírez Sara; Signore Alberto
Journal:  J Clin Med       Date:  2022-09-04       Impact factor: 4.964

10.  Somatostatin receptor scintigraphy in patients with rheumatoid arthritis and secondary Sjögren's syndrome treated with Infliximab: a pilot study.

Authors:  L K Anzola-Fuentes; M Chianelli; F Galli; A W J M Glaudemans; L Martin Martin; V Todino; A Migliore; A Signore
Journal:  EJNMMI Res       Date:  2016-06-04       Impact factor: 3.138

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.